Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. NRT Harm Reduction Indication Could Be Model For U.S.

This article was originally published in The Tan Sheet

Executive Summary

The U.K.'s harm reduction indication for a nonprescription nicotine replacement therapy inhaler could bode well for GlaxoSmithKline's request that FDA allow a similar change for NRT products in the U.S
Advertisement

Related Content

FDA Asks For Road Map To Broader NRT Indications
FDA Asks For Road Map To Broader NRT Indications
Advisory Committee On NRT Indications Appears Likely Following Workshop
Advisory Committee On NRT Indications Appears Likely Following Workshop
FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds
CDER-Tobacco Center Joint Meeting Could Signal Talks On NRT Indications
NRT Petition Calls On FDA To Greatly Expand Indications, Availability
GSK Asks FDA To Mull Expansion Of NRT Indications
GSK Asks FDA To Mull Expansion Of NRT Indications
Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation

Topics

Advertisement
UsernamePublicRestriction

Register

PS103808

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel